Skip to main content
Log in

Dysplastischer melanozytärer Nävus

Dysplastic melanocytic nevus

  • Schwerpunkt
  • Published:
Der Pathologe Aims and scope Submit manuscript

Zusammenfassung

Der dysplastische melanozytäre Nävus ist nach wie vor klinisch und histologisch eine umstrittene Entität. Das Auftreten dysplastischer Nävi wird insbesondere beim Nachweis eines dysplastischen Nävussyndroms mit einem erhöhten Risiko für ein malignes Melanom assoziiert. Folgende histologische Kriterien sollten zumindest erfüllt sein: Form- und größenvariante, teilweise horizontal gelegene und konfluierende Melanozytennester, Proliferation einzelner Melanozyten basal und suprabasal (sog. „lentiginöse Melanozytenhyperplasie“), atypische Melanozyten und subepidermale Fibroplasie. Das biologische Verhalten (gewöhnliche Nävusvariante oder Melanomvorläufer?) lässt sich mit den bisher zur Verfügung stehenden Methoden noch nicht verlässlich einschätzen. Die weitergehende Entwicklung molekularbiologischer Techniken sollte es ermöglichen, die prognostische Einschätzung des dysplastischen melanozytären Nävus objektiver und reproduzierbarer zu gestalten. Vor diesem Hintergrund sind für die alltägliche Praxis die komplette Entfernung der Läsion und die klinische Befundkontrolle zu empfehlen.

Abstract

Dysplastic nevus is still a controversial entity both clinically and histologically. The occurrence of dysplastic nevus especially in the context of dysplastic nevus cell syndrome is associated with an increased risk for melanoma. The following minimal histological criteria should be fulfilled: nests of melanocytes varying in size and shape, bridging and confluent, proliferation of single melanocytes basal and suprabasal, cytoplasmic and nuclear atypia of melanocytes and subepidermal fibroplasia. The biological behavior (common nevus variant or precursor of melanoma?) is difficult to evaluate by presently available methods. The further development of new molecular biology techniques may allow a better prognosis of dysplastic nevi in an objective and reproducible manner. Against this background complete excision followed by clinical surveillance has to be recommended for the routine practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6

Literatur

  1. Ackerman AB (1988) What nevus is dysplastic, a syndrome and the commonest precursor of malignant melanoma? A riddle and an answer. Histopathology 13:241–256

    Article  CAS  PubMed  Google Scholar 

  2. Arumi-Uria M (2008) Dysplastic nevus: the eye of the hurricane. J Cutan Pathol 35(Suppl 2):16–19

    Article  PubMed  Google Scholar 

  3. Barnhill RL, Cerroni L, Cook M et al (2010) State of the art, nomenclature, and points of consensus and controversary concerning benign melanocytic lesions: outcome of an international workshop. Adv Anat Pathol 17(2):73–90

    Article  PubMed  Google Scholar 

  4. Bauer J, Bastian BC (2007) Molekulargenetische Analyse bei der Diagnose melanozytärer Tumoren. Pathologe 28:464–473

    Article  CAS  PubMed  Google Scholar 

  5. Campoli M, Fitzpatrick JE, High W, Ferrone S (2012) HLA antigen expression in melanocytic lesions: is acquisition of HLA antigen expression a biomarker of atypical (dysplastic) melanocytes? J Am Acad Dermatol 66(6):911.e1–8

    Article  CAS  PubMed  Google Scholar 

  6. Cawley EP, Kruse WT, Pinkus HK (1952) Genetic aspects of malignant melanoma. AMA Arch Derm Syphilol 65:440–450

    Article  CAS  PubMed  Google Scholar 

  7. Clark WHJ, Reimer RR, Greene M et al (1978) Origin of familial malignant melanomas from heritable melanocytic lesions. „The B-K-Mole Syndrome“. Arch Dermatol 114:732–738

    Article  PubMed  Google Scholar 

  8. Conway K, Edmiston SN, Khondker ZS et al (2011) DNA-methylation profiling distinguishes malignant melanomas from benigne nevi. Pigment Cell Melanoma Res 24(2):352–360

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Duffy K, Grossman D (2012) The dysplastic nevus: from historical perspective to management in the modern era. Part I. Historical, histological, and clinical aspects. J Am Acad Dermatol 67:1.e1–16

    Article  PubMed Central  PubMed  Google Scholar 

  10. Duffy K, Grossman D (2012) The dysplastic nevus: from historical perspective to management in the modern era. Part II. Molecular aspects and clinical management. J Am Acad Dermatol 67:19.e1–12

    Article  PubMed Central  PubMed  Google Scholar 

  11. Elder DE, Goldman LI et al (1980) Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer 46:1787–1794

    Article  CAS  PubMed  Google Scholar 

  12. Elder DE (2010) Dysplastic nevi: an update. Histopathology 56(1):112–120

    Article  PubMed  Google Scholar 

  13. Farber MJ, Heilma ER, Friedman RJ (2012) Dysplastic nevi. Dermatol Clin 30(3):389–404

    Article  CAS  PubMed  Google Scholar 

  14. Friedman RJ, Farber MJ et al (2009) The „dysplastic“ nevus. Clin Dermatol 27(1):10315

    Article  Google Scholar 

  15. Gao L, Hurk K van den, Moerkerk PT et al (2014) Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy. J Invest Dermatol (accepted article/Epub ahead of print)

  16. Hall BJ, LeBoit PE (2014) Suprabasal spread of melanocytes in dysplastic nevi and melanoma in situ: Ki-67-labeling rate of junctional melanocytes and suprabasal cells may be a helpful clue to the diagnosis. Am J Surg Pathol 38(8):1111–1117

    PubMed  Google Scholar 

  17. Hürlimann AF, Hardmeier T (1991) Dysplastic nevus: morphologic criteria for diagnosis. Pathologe 12(1):5–12

    PubMed  Google Scholar 

  18. Hussein MR, Roggero E, Sudilovsky EC et al (2001) Alterations of mismatch repair protein expression in benign melanocytic nevi, melanocytic dysplastic nevi, and cutaneous malignant melanomas. Am J Dermatopathol 23(4):308–314

    Article  CAS  PubMed  Google Scholar 

  19. Hussein MR, Sun M, Tuthill RJ et al (2001) Comprehensive analysis of 112 melanocytic skin lesions demonstrates microsatellite instability in melanomas and dysplastic nevi, but not in benign nevi. J Cutan Pathol 28(7):343–350

    Article  CAS  PubMed  Google Scholar 

  20. Huwait H, Hijazi N et al (2014) The significance of Melan-A-positive pagetoid melanocytes in dysplastic nevi. Am J Dermatopathol 36(4):340–343

    Article  PubMed  Google Scholar 

  21. Kiszner G, Wichmann B et al (2014) Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in the thick melanomas. Virchows Arch 464(5):603–612

    Article  CAS  PubMed  Google Scholar 

  22. Kozubek J, Ma Z et al (2013) In-depth characterization of microRNA transcriptome in melanoma. PLoS One 8(9):e72699

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Lynch HT, Frichot BC III, Lynch JF (1978) Familial atypical multiple mole-melanoma syndrome. J Med Genet 15:352–356

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Massi G, LeBoit PE (2014) Histological diagnosis of nevi and melanoma, Chapter 17, 2. Aufl. Springer, Berlin Heidelberg New York, S 273–284

  25. Norris W (1820) A case of fungoid disease. Edinb Med Surg J 16:562

    Google Scholar 

  26. North JP, Garrido MC et al (2014) Fluorescence in situ hybridization as an ancillary tool in the diagnosis of ambiguous melanocytic neoplasms: a review of 804 cases. Am J Surg Pathol 38(6):824–831

    Article  PubMed  Google Scholar 

  27. Pozo L, Naase M, Cerio R et al (2001) Critical analysis of histologic criteria for grading atypical (dysplastic) melanocytic nevi. Am J Clin Pathol 115:194–204

    Article  CAS  PubMed  Google Scholar 

  28. Rubben A, Bogdan I, Grussendorf-Conen EI et al (2002) Loss of heterozygosity and microsatellite instability in acquired melanocytic nevi: towards a molecular definition of dysplastic nevi. Recent Results Cancer Res 160:100–110

    Article  PubMed  Google Scholar 

  29. Rudolph P (2002) Der dysplastische Nävus. Ein Ariadnedfaden durch ein konzeptionelles Labyrinth. Pathologe 23:128–134

    Article  CAS  PubMed  Google Scholar 

  30. Shpitz B, Klein E, Malinger P et al (2005) Altered expression of the DNA mismatch repair proteins hMLH1 and hMSH2 in cutaneous dysplastic nevi and melanoma. Int J Biol Markers 20(1):65–68

    CAS  PubMed  Google Scholar 

  31. Xu Y, Brenn T et al (2012) Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and acta s tumour suppressors. Br J Cancer 106(3):553–561

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Zhang G, Li G (2012) Novel multiple markers to distinguish melanoma from dysplastic nevi. PLoS One 7(9):e45037

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Danksagung

Ein besonderer Dank gilt den ärztlichen Kollegen des Heinz-Werner-Seifert-Instituts für Dermatopathologie, Bonn, für die stete diagnostische Unterstützung und die anregenden Diskussionen.

Einhaltung ethischer Richtlinien

Interessenkonflikt. E. Bierhoff gibt an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to E. Bierhoff.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bierhoff, E. Dysplastischer melanozytärer Nävus. Pathologe 36, 46–52 (2015). https://doi.org/10.1007/s00292-014-2061-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00292-014-2061-5

Schlüsselwörter

Keywords

Navigation